ROBIN L. SMITH

Corporate Board Profile

Tech Score: 0/100

Emmaus Life Sciences, Inc.

Filing Date	Source Excerpt
2015-10-06	Robin L. Smith, MD joined our Board of Directors as its Chairman on August 20, 2015. Dr. Smith is currently also the Chairman of the Board of Directors of Caladrius Biosciences (formerly NeoStem) (NASDAQ:CLBS), an emerging cellular therapy business, was Executive Chairman of NeoStem from January 2015 through June 2015 after having previously served as Chairman and Chief Executive Officer of Caladrius Biosciences from 2006 to 2015. Dr. Smith was selected to serve as our Chairman of the Board of Directors because of her extensive experience in the management, marketing and funding of emerging medical technology companies. The following table below sets forth the membership of each Committee: Robin Smith Chair Governance and Nominations Committee.
2018-11-02	Robin Smith (1) 237,500 Fees Earned or Paid in Cash, 135,040 Option Awards ($), 38,750 Stock Awards ($), Total ($) 411,290

Filing Date

Source Excerpt

2015-10-06

Robin L. Smith, MD joined our Board of Directors as its Chairman on August 20, 2015. Dr. Smith is currently also the Chairman of the Board of Directors of Caladrius Biosciences (formerly NeoStem) (NASDAQ:CLBS), an emerging cellular therapy business, was Executive Chairman of NeoStem from January 2015 through June 2015 after having previously served as Chairman and Chief Executive Officer of Caladrius Biosciences from 2006 to 2015. Dr. Smith was selected to serve as our Chairman of the Board of Directors because of her extensive experience in the management, marketing and funding of emerging medical technology companies. The following table below sets forth the membership of each Committee: Robin Smith Chair Governance and Nominations Committee.

2018-11-02

Robin Smith (1) 237,500 Fees Earned or Paid in Cash, 135,040 Option Awards ($), 38,750 Stock Awards ($), Total ($) 411,290

Data sourced from SEC filings. Last updated: 2026-02-03